<DOC>
	<DOCNO>NCT01585298</DOCNO>
	<brief_summary>Study evaluate bradycardiac event first dose observation fingolimod MS patient</brief_summary>
	<brief_title>STudy vAlidate telemetRic ECG Systems firsT Dose Administration Fingolimod ( START )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Subjects relapse remit MS high disease activity despite treatment disease modify therapy ( &gt; 1 relapse previous year , &gt; 9 hyperintense T2 lesion &gt; 1 Gdenhancing lesion `` nonresponding '' could define unchanged increase relapse rate ongoing severe relapse compare previous year ) patient rapidly evolve severe RRMS ( e.g . &gt; 2 relapse disease progression one year &gt; 1 Gdenhancing lesion significant increase T2 lesion compare recent MRI ) . immunocompromised patient active infection pregnant nursing woman , woman childbearing potential unless use 2 reliable form contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MS</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Gilenya</keyword>
	<keyword>ECG</keyword>
	<keyword>Bradyarrythmia</keyword>
	<keyword>conduction abnormality</keyword>
	<keyword>first dose observation</keyword>
</DOC>